Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCT of Daytrana, Vyvanse, Concerta, and Adderall XR in ADHD
NCT00889915Phase 4Completed
- Sponsor
- Duke University
- Start
- Apr 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methylphenidate and lisdexamfetamine in attention deficit hyperactivity disorder (ADHD) (4 arms), sponsored by Duke University. Primary endpoint: Clinical Global Impression-Effectiveness Scale at 6 weeks. Started Apr 2009; status: completed.
02
Drugs
methylphenidatelisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00889915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00889915.